DrugPatentWatch Database Preview
Drugs in Development Information for RG1662
» See Plans and Pricing
What is the development status for investigational drug RG1662?
RG1662 is an investigational drug.
There have been 9 clinical trials for RG1662.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are thirteen US patents protecting this investigational drug and one hundred and fifty-three international patents.
Summary for RG1662
| US Patents | 13 |
| International Patents | 153 |
| US Patent Applications | 29 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2014-05-01) |
| Vendors | 27 |
Recent Clinical Trials for RG1662
| Title | Sponsor | Phase |
|---|---|---|
| A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age | Hoffmann-La Roche | Phase 2 |
| A Brain Imaging Study to Assess GABAA Receptor Alpha5 Subunit Occupancy Following a Single Dose of RO5186582 in Japanese Healthy Volunteers. | Hoffmann-La Roche | Phase 1 |
| A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects | Hoffmann-La Roche | Phase 1 |
Clinical Trial Summary for RG1662
Top disease conditions for RG1662
Top clinical trial sponsors for RG1662
US Patents for RG1662
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RG1662 | Get Started for $10 | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Get Started for $10 |
| RG1662 | Get Started for $10 | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Get Started for $10 |
| RG1662 | Get Started for $10 | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | Get Started for $10 |
| RG1662 | Get Started for $10 | Compositions and methods for neurological diseases | Coda Biotherapeutics, Inc. (South San Francisco, CA) | Get Started for $10 |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RG1662
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RG1662 | Australia | AU2017261372 | 2036-05-05 | Get Started for $10 |
| RG1662 | Canada | CA3023278 | 2036-05-05 | Get Started for $10 |
| RG1662 | China | CN107847398 | 2036-05-05 | Get Started for $10 |
| RG1662 | European Patent Office | EP3452003 | 2036-05-05 | Get Started for $10 |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
